Contribute Try STAT+ Today

Boston

Most Read

Lab mouse on green

Health By Eric Boodman

Researchers rush to test coronavirus vaccine in people without knowing how well it works in animals

John Bonfiglio_1

Health By Elizabeth Cooney

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

blue sky moderna

Biotech By Helen Branswell

Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine

Health By Matthew Herper and Damian Garde

First data for Moderna Covid-19 vaccine show it spurs an immune response

Vinnie Family 01

A STAT Investigation By Eric Boodman

Cement Head’s last fight: He was denied parole six times — until he was about to become a Covid-19 statistic

2019-nCoV

In the Lab By Sharon Begley

DNA sleuths read the coronavirus genome, tracing its origins and looking for dangerous mutations

Charlie Baker

Health By Rebecca Ostriker and Andrea Estes — The Boston Globe

The inside story of a Covid-19 outbreak that killed 76 veterans at a Massachusetts senior-care center

ß-lactamase-producing Enterobacteriaceae

Health By Kate Sheridan

Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows

All Coverage

Health By Kevin Lin

How a new buddy system is helping health workers grapple with Covid’s toll

2020 Biogen

Biotech By Felice J. Freyer — Boston Globe

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

advertisement

person walking past NYSE

Biotech By Adam Feuerstein

German drug maker MorphoSys to buy Constellation Pharma in $1.7 billion deal

Sharon at Summit

Health By Andrew Joseph

Aiming to diversify science journalism, STAT creates fellowship named for reporter Sharon Begley

Eye health

Biotech By Jonathan Saltzman — Boston Globe

Atlas Venture launches another biotech to tackle vision loss

Smartphone & medicine illustration

Health Tech By Mario Aguilar

Inside Pear’s ambitious plan to become the most dominant player in digital therapeutics

MODERNA - Norwood facility

Biotech By Jonathan Saltzman — Boston Globe

Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents

blue abstract dna

Biotech By Anissa Gardizy — Boston Globe

Dyno raises $100 million to bring artificial intelligence to gene therapy

ASH19 Gene Therapy Sickle Cell

Biotech By Megan Molteni

Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation

Cash on yellow background

Biotech By Anissa Gardizy — Boston Globe

Adagio raises $336 million to advance Covid-19 antibody treatment

Thermo Fisher Scientific

Biotech By Anissa Gardizy — Boston Globe

Thermo Fisher buys contract-research company PPD for $17.4 billion

Human Colon Cancer Cells

Biotech By Anissa Gardizy — Boston Globe

Tango Therapeutics to go public in $353 million SPAC deal

Nancy Hopkins

Biotech By Rebecca Sohn

‘As good a model as I’ve seen’: MIT biologist on new initiative to address gender inequities in biotech

Peter Slavin

Hospitals By Priyanka Dayal McCluskey — Boston Globe

Massachusetts General Hospital president Peter Slavin to depart after 18 years

Biotech By Anissa Gardizy — Boston Globe

MIT scientists launch Future Founders Initiative to solve biotech’s ‘missing women’ problem

Globe illo for med chiefs

Hospitals By Liz Kowalczyk, Sarah L. Ryley, Mark Arsenault, and Patricia Wen — Boston Globe

Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level

Broad Institute building

In the Lab By Scott Kirsner — Boston Globe

The Broad Institute’s new leader wants to ‘double down’ on biology

Cambridge: Biogen

Biotech By Adam Feuerstein and Damian Garde

FDA delays approval decision for Biogen’s Alzheimer’s treatment

Biotech By Larry Edelman — Boston Globe

After Moderna’s medical miracle, some investors step back

By Casey Ross and Erin Brodwin

‘What was left for Haven?’: How Amazon’s health ambitions devoured Haven’s plans

Surprise bills concept

Biotech By Anissa Gardizy — Boston Globe

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

Progeria - Magali Gonzalez Sierra

In the Lab By Sharon Begley

CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging

First Opinion By Shirley Leung

‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well

Microscope

Biotech By Anissa Gardizy — Boston Globe

New biotech backed by Third Rock launches with $81 million to go after ALS, other diseases

Cambridge: Biogen

Pharmalot By Ed Silverman

Federal watchdog urged to investigate the FDA’s handling of Biogen Alzheimer’s drug